On June 22, 2015, Pfizer Inc. announced that it entered an agreement with GlaxoSmithKline to acquire the meningitis vaccines Nimenrix and Mencevax. The acquisition will cost approximately $130 million USD and is expected to occur in the second half of 2015. The vaccine acquisition will allow Pfizer to service a broader population. This acquisition is not expected to have a significant financial impact on Pfizer’s 2015 financial performance and is subject to customary closing conditions and regulatory approvals.
Nimenrix (meningococcal serogroups A, C, W-135 and Y conjugate vaccine) is a meningococcal ACWY-TT conjugated vaccine that protects against Neisseria meningitidis. Nimenrix became available three years ago and is approved for sale in 61 countries and it’s registration is under review in 18 countries.
Mencevax (meningococcal polysaccharide serogroups A, C, Y and W-135 vaccine) is a meningococcal ACWY unconjugated polysaccharide vaccine used against meningococcal outbreaks and for travelers. Mencevax is available in 79 countries.
President of Pfizer Vaccines, Susan Silbermann said, “The addition of Nimenrix and Mencevax is an important milestone for Pfizer Vaccines. Adding these two innovative and complementary vaccines to our current portfolio will allow us to more completely respond to meningococcal disease outbreaks as well as proactively address a critical public health need – the prevention of meningococcal disease across all ages. Acquiring these quadrivalent vaccines will broaden our ability to address the burden of meningococcal meningitis – an uncommon but serious and sometimes fatal disease. This helps us to further fulfill our vision to protect lives with innovative vaccines to fight serious diseases worldwide and gives us even greater capability to meet the needs of the global community we serve.”
Pfizer’s goal for several years has been to bring new therapies to patients that significantly improve their lives. Pfizer Vaccines has the goal to increase business and enhance their portfolio through targeted external opportunities.
About Nimenrix and Mencevax
Nimenrix is indicated for active immunization of individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135 and Y.
Mencevax is indicated for active immunization of children older than two years, adolescents and adults against invasive meningococcal disease caused by meningococci of groups A, C, W135 and Y.
About Pfizer Inc.
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
No comments:
Post a Comment